Preimplantation genetic diagnosis (PGD) also referred as embryo screening, is a branch of genetics involves in genetic testing of embryo through in-vitro fertilization (IVF). PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal, or hereditary disorders such as spinal muscular atrophy and cystic fibrosis.
The global PGD market size is estimated to be $79.5 million in 2015 and expected to reach $121.5 million registering a CAGR of 6.14% from 2016 to 2022. The global PGD market is expected to witness notable growth in the near future owing to the rise in prevalence of genetic, hereditary, and chromosomal diseases. Moreover, PGD have high chances of conceiving healthy embryos. However, the high costs incurred in the PGD technologies hamper the market growth. Moreover, stringent government regulations and ethical concerns also obstruct the market growth. In the near future, increase is expected in adoption of PGD worldwide owing to its various applications for development of healthy embryo.
The global PGD market is segmented based on the test type and geography. Based on type, the market can be segmented into aneuploidy, chromosomal abnormalities, gender selection, HLA typing, single gene disorder, X-linked diseases, and others (disability, and adult onset disease). Geographically, the market is segmented into North America, Europe, Asia-Pacific and LAMEA.
The key market players are Reprogenetics, LLC, Genea Limited, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Genesis Genetics Ltd., and Reproductive Genetics Innovations LLC.
KEY MARKET BENEFITS:
In-depth study of the global preimplantation genetic diagnostic market was conducted based on current testing trends of genetic test and based on the preferences for designer babies
Potential analysis of opportunities was evaluated for understanding different aspects of preimplantation genetic test that are currently under various phases of clinical trials along with the variants that would gain prominence in the future
A deep analysis of key market dynamics that influence the adoption of PGD tests in the forecast period
Analysis of volume and vale share analysis of PGD testing at a global and regional level
Key market players are profiled and their strategies are analyzed thoroughly for understanding the various technologies adopted by them for development and production of diagnostic tests for PGD testing
KEY MARKET SEGMENT:
By Test Type
Chromosomal abnormalities
Gender selection
X-linked diseases
Aneuploidy
Single gene disorders
Others
By Region
North America
Europe
Asia-Pacific
LAMEA
Key Benefits
The report provides an in-depth analysis of the PGD market with current and future estimates to elucidate the investment pockets
Current and future trends are outlined to determine the overall attractiveness market and to single out profitable trends to gain a stronger foothold in the market
The report provides information regarding key drivers, restraints, and opportunities along with their impact analysis on the PGD market
Quantitative analysis of the current market and estimations for 2014-2022 is provided to understand the financial competency of the market
Porters Five Forces Model of the industry illustrates the potency of the buyers & suppliers participating in the market
Comprehensive analyses of all regions are provided to determine the predominant opportunities in these geographies
Key market players of PGD market are analyzed to understand the competitive outline of the global PGD market
Key Market Segments
BY TYPE
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single Gene Disorder
HLA Typing
Gender Selection
Others
BY GEOGRAPHY:
North America
Europe
Asia-Pacific
LAMEA